Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
[Paeoniflorin alleviates cancer-related fatigue during chemotherapy for breast cancer by targeting EZH2/CCNE1 to regulate cell cycle and inflammatory microenvironment].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Zhuang, Shi Huan, Chen Jieting, Liang Yuqi, Wu Yingchao, Zuo Qian, Chen Qianjun
Аннотация
OBJECTIVES: To explore the molecular mechanisms and key pharmacodynamic basis of Baishao for alleviating cancer-related fatigue (CRF) during chemotherapy for breast cancer.
METHODS: Bioinformatics analyses were used to explore the active ingredients and potential targets of Baishao, CRF-related targets, and the differentially expressed core genes between chemotherapy and non-chemotherapy groups. Four machine learning algorithms (Random Forest, SVM, XGBoost, and GLM) were used to screen the key feature genes to construct a diagnostic nomogram model with subsequent survival and immunohistochemical analyses using Kaplan-Meier Plotter and HPA databases. In an IL-17-induced Py230 breast cancer cell model of CRF, the regulatory effects of paeoniflorin (a major active ingredient of Baishao) on the core targets were validated using CCK-8 assay, qRT-PCR, Western blotting, and immunofluorescence staining.
RESULTS: Thirteen active ingredients (including paeoniflorin, albiflorin, and kaempferol) and 475 drug targets of Baishao were identified, yielding 65 core intersection genes enriched in the MAPK signaling cascade, circadian rhythm, and cell cycle regulation and showing significant correlations with immune cells. The SVM model demonstrated the best diagnostic performance and identified PSMB8, EZH2, CCNE1, PSEN2, and CDK1 as the key feature genes. The SVM-based nomogram achieved a C-index of 0.911, showing excellent calibration and clinical net benefit. Molecular docking confirmed strong binding affinities between the core ingredients of Baishao and the key targets. Survival analysis linked high EZH2 and CCNE1 expressions to poor breast cancer prognosis. In IL-17-induced Py230 cells, chemotherapy resulted in significant upregulation of EZH2 and CCNE1 expressions, which were effectively reversed by paeoniflorin treatment with an efficacy comparable to specific positive inhibitors.
CONCLUSIONS: Paeoniflorin alleviates chemotherapy-induced CRF in breast cancer by targeting and inhibiting abnormal expressions of EZH2 and CCNE1 to regulate cell cycle and inflammatory microenvironment, highlighting the therapeutic potential of Baishao for attenuating toxicity and enhancing efficacy of chemotherapy.
METHODS: Bioinformatics analyses were used to explore the active ingredients and potential targets of Baishao, CRF-related targets, and the differentially expressed core genes between chemotherapy and non-chemotherapy groups. Four machine learning algorithms (Random Forest, SVM, XGBoost, and GLM) were used to screen the key feature genes to construct a diagnostic nomogram model with subsequent survival and immunohistochemical analyses using Kaplan-Meier Plotter and HPA databases. In an IL-17-induced Py230 breast cancer cell model of CRF, the regulatory effects of paeoniflorin (a major active ingredient of Baishao) on the core targets were validated using CCK-8 assay, qRT-PCR, Western blotting, and immunofluorescence staining.
RESULTS: Thirteen active ingredients (including paeoniflorin, albiflorin, and kaempferol) and 475 drug targets of Baishao were identified, yielding 65 core intersection genes enriched in the MAPK signaling cascade, circadian rhythm, and cell cycle regulation and showing significant correlations with immune cells. The SVM model demonstrated the best diagnostic performance and identified PSMB8, EZH2, CCNE1, PSEN2, and CDK1 as the key feature genes. The SVM-based nomogram achieved a C-index of 0.911, showing excellent calibration and clinical net benefit. Molecular docking confirmed strong binding affinities between the core ingredients of Baishao and the key targets. Survival analysis linked high EZH2 and CCNE1 expressions to poor breast cancer prognosis. In IL-17-induced Py230 cells, chemotherapy resulted in significant upregulation of EZH2 and CCNE1 expressions, which were effectively reversed by paeoniflorin treatment with an efficacy comparable to specific positive inhibitors.
CONCLUSIONS: Paeoniflorin alleviates chemotherapy-induced CRF in breast cancer by targeting and inhibiting abnormal expressions of EZH2 and CCNE1 to regulate cell cycle and inflammatory microenvironment, highlighting the therapeutic potential of Baishao for attenuating toxicity and enhancing efficacy of chemotherapy.